British drug-development company has spun out a Boston subsidiary called Trident Pharmaceuticals Inc. The firm is backed by up to $15 million, with investors including Hunter-Fleming Ltd. and Advent International of Boston. Trident will use the funding to develop a compound to treat asthma and allergic conditions by activating a sufferer’s own immune regulatory system. The compound, termed HF1020, was originally developed at Bristol University in the United Kingdom.
